TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9222674

Group type: EXPERIMENTAL
Intervention: Submucosal saline injection
Number of subjects: 57

Group type: COMPARATOR
Intervention: No submucosal saline injection
Number of subjects: 57
Study: 8109212

Group type: EXPERIMENTAL
Intervention: Argon green laser photocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Argon blue-green laser photocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Krypton red laser photocoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Argon green and argon blue-green lasers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Argon blue-green laser
Number of subjects: 0
Study: 3651264

Group type: EXPERIMENTAL
Intervention: Split-course radiation therapy with a 3-week rest interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Split-course radiation therapy with a 5-week rest interval
Number of subjects: 0
Study: 30892640

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 534
Study: 27908492

Group type: EXPERIMENTAL
Intervention: TTC nailing (Group A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: ORIF (Group B)
Number of subjects: 87
Study: 26021563

Group type: EXPERIMENTAL
Intervention: Intraoperative brief electrical stimulation (BES) for 60 min continuously at 20 Hz, 3 to 5 V, in 100‐msec pulses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative brief electrical stimulation (BES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24364800

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention, 4 sessions
Number of subjects: 143

Group type: COMPARATOR
Intervention: Content-matched education, 4 sessions
Number of subjects: 143
Study: 21545527

Group type: EXPERIMENTAL
Intervention: Moderate exercise program (endurance and activity of daily living training, twice a day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard physiotherapy program (once a day)
Number of subjects: 47
Study: 19702817

Group type: EXPERIMENTAL
Intervention: Cardiac-Diabetes Self-Management Program (CDSMP)
Number of subjects: 0
Study: 17350452

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA) 24 microg/kg/h for 96 h
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA)
Number of subjects: 477
Study: 15142004

Group type: EXPERIMENTAL
Intervention: 12-week training program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 25
Study: 11468940

Group type: EXPERIMENTAL
Intervention: Wald's approximation to the likelihood ratio test (LRT) statistic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full model fit of k covariate parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model selection and validation
Number of subjects: 0
Study: 9737496

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7635025

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation around the time of conception and in early pregnancy
Number of subjects: 2000
Study: 3117400

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) group, intravesical instillation with 50 mg ADM dissolved in 100 ml physiological saline; administered six times within 2 weeks, then every 4 weeks for 2 years.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) group, intravesical instillation with 30 mg MMC dissolved in 100 ml physiological saline; administered six times within 2 weeks, then every 4 weeks for 2 years.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group, transurethral resection or transurethral coagulation alone; no drug intervention.
Number of subjects: 103
Study: 31609926

Group type: EXPERIMENTAL
Intervention: Zinc gluconate capsules at a dose of 45 mg (low-dose) daily for 16 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Zinc gluconate capsules at a dose of 90 mg (high-dose) daily for 16 weeks
Number of subjects: 52
Study: 28919811

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study: 25133827

Group type: EXPERIMENTAL
Intervention: Early provision of normal test results immediately following testing
Number of subjects: 51

Group type: COMPARATOR
Intervention: Results provided 4 weeks later
Number of subjects: 51
Study: 23392882

Group type: EXPERIMENTAL
Intervention: Combination of 2.0 g TAU and 3.2 g BCAA, thrice a day, for 2 weeks prior to and 4 days after exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: BCAA alone (3.2 g)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TAU alone (2.0 g)
Number of subjects: 36
Study: 21843919

Group type: EXPERIMENTAL
Intervention: Tumour resection plus tamoxifen (T + T)
Number of subjects: 71
Study: 19392869

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) / Mercaptopurine (MP)
Number of subjects: 1632
Study: 17244641

Group type: EXPERIMENTAL
Intervention: Early routine post-fibrinolysis angioplasty
Number of subjects: 212

Group type: COMPARATOR
Intervention: Primary angioplasty
Number of subjects: 212
Study: 12622759

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG supplementation (10 LGG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (10 placebo)
Number of subjects: 20
Study: 11137327

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy with E2 (50 microg/day) and NETA (170 microg/day)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy with E2 (50 microg/day) and NETA (350 microg/day)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Transdermal hormone replacement therapy with E2 and sequential oral progestogen
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy with lower dose of NETA (170 microg/day)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy with higher dose of NETA (350 microg/day)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 367
Study: 8959465

Group type: EXPERIMENTAL
Intervention: Minaprine (antidepressant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or other antidepressants not specified)
Number of subjects: 0
Study: 1549951

Group type: EXPERIMENTAL
Intervention: Intervention group with reminders and recall letter
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Intervention group with reminders only
Number of subjects: 546

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 546
Study: 4025772

Group type: EXPERIMENTAL
Intervention: Spinal analgesia with bupivacaine 0.75%
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia with diazepam, fentanly and N2O/O2
Number of subjects: 40
Study: 30574790

Group type: COMPARATOR
Intervention: Standard dose enoxaparin (1 mg/kg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Reduced dose enoxaparin (0.8 mg/kg)
Number of subjects: 62
Study: 30194765

Group type: EXPERIMENTAL
Intervention: Therapeutic levels of hypoglossal nerve stimulation therapy (HGNS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subtherapeutic levels of hypoglossal nerve stimulation therapy (HGNS)
Number of subjects: 60
Study: 25933911

Group type: EXPERIMENTAL
Intervention: Synbiotics treatment
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 362
Study: 25495109

Group type: EXPERIMENTAL
Intervention: Multimorbidity collaborative care program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 22750451

Group type: COMPARATOR
Intervention: SGA infants
Number of subjects: 139
Study: 20056901

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 21
Study: 18281656

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg PO bid
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg PO qid
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Celecoxib and Zileuton at the same doses
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no celecoxib)
Number of subjects: 134
Study: 15963058

Group type: EXPERIMENTAL
Intervention: Low dose testosterone (Te) supplementation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High dose testosterone (Te) supplementation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 15
Study: 12676601

Group type: EXPERIMENTAL
Intervention: Combustion particles (1.0 mg/m3) followed by allergen challenge
Number of subjects: 8

Group type: COMPARATOR
Intervention: Combustion particles (1.0 mg/m3)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Clean air followed by allergen
Number of subjects: 8

Group type: COMPARATOR
Intervention: Particles followed by no allergen
Number of subjects: 8
Study: 10760528

Group type: EXPERIMENTAL
Intervention: Pre-eclamptic women
Number of subjects: 75
Study: 8991550

Group type: EXPERIMENTAL
Intervention: Overnight pulse oximetry (PO)
Number of subjects: 20
Study: 1424429

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan and carbidopa
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: levodopa and carbidopa
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 3008313

Group type: EXPERIMENTAL
Intervention: i.v. applicable CMV-hyperimmunoglobulin administered prior to transplant
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 83
Study: 31142032

Group type: EXPERIMENTAL
Intervention: MATRI‐SUMAN intervention
Number of subjects: 379
Study: 29921339

Group type: EXPERIMENTAL
Intervention: Smartphone-based digital images for cervical cancer screening
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Assessment by gynecologists (45 total, with varying experience)
Number of subjects: 125
Study: 26340981

Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice (550 ppm F) at pH 4.5
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1100 ppm F) at pH 4.5
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (0 ppm F) at pH 4.5
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice (550 ppm F) at pH 7.0
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1100 ppm F) at pH 7.0
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (0 ppm F) at pH 7.0
Number of subjects: 22
Study: 25239590

Group type: EXPERIMENTAL
Intervention: Prucalopride (0.04 mg/kg oral solution for children ≤ 50 kg; 2 mg tablet for children > 50 kg) once daily for 8 weeks
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo once daily for 8 weeks
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 22797101

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 100
Study: 20141583

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) extracts, 3 capsules of 1 g per capsule daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17215475

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 16131622

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrelated control
Number of subjects: 0
Study: 11669594

Group type: EXPERIMENTAL
Intervention: Group A: short-term intra-arterial infusion of 550 mg/m² 5-FU (days 1-4) plus 80 µg/m² GM-CSF (day 1+2) combined with chemoembolization with 25 mg/m² melphalan plus Lipiodol and Gelfoam (day 5)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Group B: continuous circadian intra-arterial infusion of 1400 mg/m² 5-FU plus 60 mg/m² i.v. leucovorin and 80 µg/m² GM-CSF (day 1+2) combined with chemoembolization with 25 mg/m² melphalan plus Lipiodol and Gelfoam (day 3)
Number of subjects: 103
Study: 9209730

Group type: EXPERIMENTAL
Intervention: Clozapine serum level 50-150 ng/mL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine serum level 200-300 ng/mL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine serum level 350-450 ng/mL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine treatment (general)
Number of subjects: 50
Study: 10155067

Group type: EXPERIMENTAL
Intervention: Intravascular sheath access
Number of subjects: 200

Group type: COMPARATOR
Intervention: Guidewire access
Number of subjects: 200
Study: 2885173

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 119

Group type: COMPARATOR
Intervention: Bromazepam
Number of subjects: 119
Study: 2142921

Group type: EXPERIMENTAL
Intervention: Intranasal buserelin (500 micrograms thrice daily for 10 days, then intranasal)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Subcutaneous goserelin
Number of subjects: 42
Study: 1096120

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 2
Study: 31845172

Group type: EXPERIMENTAL
Intervention: Endoscopic procedure (group A)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Decompressive craniectomy (group B)
Number of subjects: 112
Study: 31482268

Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (tDCS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 94
Study: 29149428

Group type: EXPERIMENTAL
Intervention: Purse-string approximation (PSA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Linear closure (PLC)
Number of subjects: 61
Study: 25078981

Group type: EXPERIMENTAL
Intervention: Retinaldehyde-based cream (RA-cream) applied once daily for 3 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control cream applied once daily for 3 months
Number of subjects: 29
Study: 23570536

Group type: EXPERIMENTAL
Intervention: Community-wide campaign (CWC) promoting physical activity from 2009 to 2010, comprising information, education, and support delivery.
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 6000
Study: 21846989

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (ELC) within 72 hours
Number of subjects: 96

Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (DLC) in 6-8 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Presence of bactobilia
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bactobilia
Number of subjects: 96
Study: 19583831

Group type: EXPERIMENTAL
Intervention: 5 HZ excitatory rTMS to PMd
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 HZ inhibitory rTMS to PMd
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study: 16620353

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Combination of ipratropium bromide and salbutamol sulphate
Number of subjects: 56
Study: 14960129

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 or 20mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vardenafil 5-20mg
Number of subjects: 0
Study: 11520010

Group type: EXPERIMENTAL
Intervention: VR exposure flights (1 test flight + 4 exposure flights)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Relaxation training (1 test flight + lengthy relaxation session)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VR exposure flights
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (VR and relaxation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 30
Study: 9480468

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic regimen (gentamicin, clindamycin)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Curative antibiotic treatment (intraoperatively)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Prophylaxis with prolonged antibiotic administration
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no prophylactic or curative antibiotics)
Number of subjects: 104
Study: 8098389

Group type: EXPERIMENTAL
Intervention: Erythropoietin (300 units/kg to a maximum of 30,000 units) for 14 days
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Erythropoietin for 9 days (starting 6 days before surgery)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 208
Study: 2433406

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, bleomycin, and methotrexate with oral calcium leucovorin (PBM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with PBM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induction chemotherapy
Number of subjects: 0
Study: 31945197

Group type: COMPARATOR
Intervention: URO-902 5000 µg
Number of subjects: 34

Group type: COMPARATOR
Intervention: URO-902 10,000 µg
Number of subjects: 34

Group type: COMPARATOR
Intervention: URO-902 16,000 µg
Number of subjects: 34

Group type: COMPARATOR
Intervention: URO-902 24,000 µg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 29316832

Group type: EXPERIMENTAL
Intervention: Individual Enabling and Support (IES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 0
Study: 27028380

Group type: EXPERIMENTAL
Intervention: Wiltse approach
Number of subjects: 69

Group type: COMPARATOR
Intervention: Traditional approach
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 69
Study: 24650323

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Maltitol chewing gum
Number of subjects: 220

Group type: COMPARATOR
Intervention: Gum base
Number of subjects: 220

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 220
Study: 23695482

Group type: EXPERIMENTAL
Intervention: Early tracheostomy (within 4 days)
Number of subjects: 909

Group type: COMPARATOR
Intervention: Late tracheostomy (after 10 days if still indicated)
Number of subjects: 909
Study: 20610442

Group type: EXPERIMENTAL
Intervention: Treatment with infliximab
Number of subjects: 13959

Group type: EXPERIMENTAL
Intervention: Treatment with methotrexate
Number of subjects: 13959

Group type: EXPERIMENTAL
Intervention: Overall analysis of joints
Number of subjects: 13959
Study: 18717606

Group type: EXPERIMENTAL
Intervention: BenzaClin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Duac
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.2% sodium laurilsulfate (SLS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: White petrolatum
Number of subjects: 40
Study: 16390893

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg/day (with titration options to 5 mg/day or 20 mg/day)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 14662212

Group type: EXPERIMENTAL
Intervention: Folic acid-containing multivitamin supplementation
Number of subjects: 2471

Group type: COMPARATOR
Intervention: Unsupplemented group
Number of subjects: 2471

Group type: EXPERIMENTAL
Intervention: Combined data of supplemented group
Number of subjects: 2471

Group type: COMPARATOR
Intervention: Combined data of unsupplemented group
Number of subjects: 2471
Study: 11287025

Group type: EXPERIMENTAL
Intervention: Lisuride maleate (0.2 mg daily for 2 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0.2 mg daily for 2 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lisuride maleate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9256832

Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin after 5 years of age
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo after 5 years of age
Number of subjects: 226
Study: 8255017

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 8
Study: 2886200

Group type: EXPERIMENTAL
Intervention: Levobunolol hydrochloride 0.5% with 2% pilocarpine (17 patients)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Levobunolol hydrochloride 1% with 2% pilocarpine (19 patients)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Timolol maleate 0.5% with 2% pilocarpine (18 patients)
Number of subjects: 54
Study: 31145549

Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels <10 ng/mL
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels ≥10 ng/mL
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Serum vitamin D level ≥10 ng/mL
Number of subjects: 496
Study: 28081633

Group type: EXPERIMENTAL
Intervention: Activity-oriented treatment (10 days, 30 minutes each day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Structural-oriented treatment (conventional therapy, 10 days, 30 minutes each day)
Number of subjects: 66
Study: 25651367

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study: 24273976

Group type: EXPERIMENTAL
Intervention: Tianxinfu adsorbable biomembrane + Ligustrazine Injection (Group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tianxinfu adsorbable biomembrane + Danhong Injection (Group D)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dikang adsorbable biomembrane (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tianxinfu adsorbable biomembrane (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 120
Study: 21804283

Group type: EXPERIMENTAL
Intervention: Periodontal intervention (T2DM-T group)
Number of subjects: 190
Study: 19695955

Group type: EXPERIMENTAL
Intervention: ATG-F
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control
Number of subjects: 201
Study: 16877662

Group type: EXPERIMENTAL
Intervention: Standard antenatal care plus the intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard antenatal care only
Number of subjects: 99
Study: 12634994

Group type: EXPERIMENTAL
Intervention: Hypericum cream (1.5% hyperforin)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 21